Русская версия English version   
О журнале
Редакционная коллегия
Правила для авторов
Информация для читателей и авторов
Оглавление текущего номера
Архив
Контакты
Поиск

Отправить статью
 


Том 9   Выпуск 2   Год 2014
Список литературы

  1. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV’s switch-hitter. AIDS Res Hum Retroviruses. 2005;21:171-189. doi: 10.1089/aid.2005.21.171
  2. Sirois S, Sing T, Chou KC. HIV-1 gp120 V3 loop for structure-based drug design. Curr. Protein Pept. Sci. 2005;6:413-422. doi: 10.2174/138920305774329359
  3. Sirois S, Touaibia M, Chou KC, Roy R. Glycosylation of HIV-1 gp120 V3 loop: towards the rational design of a synthetic carbohydrate vaccine. Curr. Med. Chem. 2007;14:3232-3242. doi: 10.2174/092986707782793826
  4. Andrianov AM. HIV-1 gp120 V3 loop for anti-AIDS drug discovery: computer-aided approaches to the problem solving. Expert Opin. Drug Discov. 2011;6:419-435. doi: 10.1517/17460441.2011.560603
  5. Hu WS, Hughes SH. HIV-1 reverse transcription. Cold Spring Harb. Perspect. Med. 2012;2(10):a006882. doi: 10.1101/cshperspect.a006882
  6. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J. Virol. 1997;71(7):5382-5390.
  7. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat. Rev. Microbiol. 2012;10(4):279-290. doi: 10.1038/nrmicro2747
  8. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 1998;92(4):451-462. doi: 10.1016/S0092-8674(00)80939-3
  9. Zimmerman C, Klein KC, Kiser PK, Singh AR, Firestein BL, Riba SC, Lingappa JR. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature. 2002;415(6867):88-92. doi: 10.1038/415088a
  10. De Clercq E. New approaches toward anti-HIV chemotherapy. J. Med. Chem. 2005;48:1297-1313. doi: 10.1021/jm040158k
  11. Este JA, Telenti A. HIV entry inhibitors. Lancet. 2007;370(9581):81-88. doi: 10.1016/S0140-6736(07)61052-6
  12. Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. An update in the development of HIV entry inhibitors. Curr. Topics in Med. Chem. 2007;7:1273-1289. doi: 10.2174/156802607781212239
  13. Ryser HJ-P, Fluckiger R. Progress in targeting HIV-1 entry. Drug Discov. Today. 2005;10:1085-1094. 
  14. Adamson CS, Freed EO. Novel approaches to inhibiting HIV-1 replication. Antiviral. Res. 2010;85:119-141. doi: 10.1016/j.antiviral.2009.09.009
  15. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010;85:91-100. doi: 10.1016/j.antiviral.2009.07.022
  16. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. Med. 2012;2(4):a007161. doi: 10.1101/cshperspect.a007161
  17. Orsega S. Treatment of adult HIV infection: antiretroviral update and overview. JNP. 2007;10:612-624. doi: 10.1016/j.nurpra.2007.08.022
  18. Vermeire K, Schols D, Bell TW. Inhibitors of HIV infection via the cellular CD4 receptor. Curr. Med. Chem. 2006;13:731-743. doi: 10.2174/092986706776055599
  19. Lin P-F, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong Y-F, Wang H-GH, Rose R, Yamanaka G, Robinson B, Li C-B, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, Colonno R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA. 2003;100(19):11013-11018. doi: 10.1073/pnas.1832214100
  20. Reimann KA, Lin W, Bixler S, Browning B, Ehrenfels BN, Lucci J, Miatkowski K, Olson D, Parish TH, Rosa MD, Oleson FB, Hsu YM, Padlan EA, Letvin NL, Burkly LC. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res. Hum. Retroviruses. 1997;13(11):933-943. doi: 10.1089/aid.1997.13.933
  21. Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003;348(22):2175-2185. doi: 10.1056/NEJMoa035026
  22. Duffalo ML, James CW. Enfuvirtide: a novel agent for the treatment of HIV-1 infection. Ann. Pharmacother. 2003;37:448-1456. doi: 10.1345/aph.1D143
  23. Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy. 2004;24:98-211. doi: 10.1592/phco.24.2.198.33141
  24. Dragic T, Trkola A, Thompson DAD, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. USA. 2000;97(10):5639-5644. doi: 10.1073/pnas.090576697
  25. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP, Dragic T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 2003;77(9):5201-5208. doi: 10.1128/JVI.77.9.5201-5208.2003
  26. Meanwell NA, Kadow JF. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr. Opin. Investig. Drugs. 2007;8:669-681.
  27. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother. 2006;57:619-627. doi: 10.1093/jac/dkl027
  28. Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, Kassa A, DeGrace M, McGee-Estrada K, Mefford M, Dana Gabuzda D, Smith AB, Sodroski1 J. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 2009;5(4):e1000360. doi: 10.1371/journal.ppat.1000360
  29. Curreli F, Choudhury S, Pyatkin I, Zagorodnikov VP, Bulay AK, Altieri A, Do Kwon Y, Kwong PD, Debnath AK. Design, synthesis and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J. Med. Chem. 2012;55:4764-4775. doi: 10.1021/jm3002247
  30. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393:648-659. doi: 10.1038/31405
  31. Floris M, Masciocchi J, Fanton M, Moro S. Swimming into peptidomimetic chemical space using pepMMsMIMIC. Nucl. Acids Res. 2011;39:261-269. doi: 10.1093/nar/gkr287
  32. Masciocchi J, Frau G, Fanton M, Sturlese M, Floris M, Pireddu L, Palla P, Cedrati F, Rodriguez-Tome P, Moro S. MMsINC: a large-scale chemoinformatics database. Nucl. Acids Res. 2009;37:D284-D290. doi: 10.1093/nar/gkn727
  33. Ballester PJ, Richards WG. Ultrafast shape recognition to search compound databases for similar molecular shapes. J. Comput. Chem. 2007;28:1711-1723. doi: 10.1002/jcc.20681
  34. Mason JS, Morize I, Menard PR, Cheney DL, Hulme C, Labaudiniere RF. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J. Med. Chem. 1999;42:3251-3264. doi: 10.1021/jm9806998
  35. Karnachi P, Kulkarni A. Application of pharmacophore fingerprints to structure-based design and data mining. In: Pharmacophores and Pharmacophore Searches. Eds. Langer T., Hoffmannn R.D. Weinheim, Germany: Wiley-VCH; 2006. P. 193-206. doi: 10.1002/3527609164.ch9
  36. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 2010;31:455-461. doi: 10.1002/jcc.21334
  37. Bernstein FC, Koetzle TF, Williams GJB, Meyer EF, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M. The protein data bank. A computer-based archival file for macromolecular structures. J. Mol. Biol. 1977;112:535-542. doi: 10.1016/S0022-2836(77)80200-3
  38. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucl. Acids Res. 2000;28:235-242. doi: 10.1093/nar/28.1.235
  39. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Crowley M, Walker RC, Zhang W, Merz KM, Wang B, Hayik S, Roitberg A, Seabra G, Kolossváry I, Wong KF, Paesani F, Vanicek J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Mathews DH, Seetin MG, Sagui C, Babin V, Kollman PA. AMBER 11. San Francisco: University of California; 2010.
  40. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983;79:926-935. doi: 10.1063/1.445869
  41. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J. Comput. Chem. 2004;25:1157-1174. doi: 10.1002/jcc.20035
  42. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977;23:327-341. doi: 10.1016/0021-9991(77)90098-5
  43. Massova I, Kollman PA. Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies. J. Am. Chem. Soc. 1999;121:8133-8143. doi: 10.1021/ja990935j
  44. Durranta JD, McCammon JA. BINANA: A novel algorithm for ligand-binding characterization. J. Mol. Graph. Model. 2011;29:888-893. doi: 10.1016/j.jmgm.2011.01.004
  45. McDonald IK, Thornton JM. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 1994;238:777-793. doi: 10.1006/jmbi.1994.1334
  46. Ablameiko SV, Abramov SM, Anishchenko VV, Medvedev SV, Paramonov NN, Chizh OP. Superkomp'iuternye konfiguratsii SKIF (SKIF Supercomputer Configurations). Minsk; 2005. 170 p. ISBN 985-6744-19-9 (in Russ.).
  47. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, Doyle ML. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. USA. 2000;97:9026-9031. doi: 10.1073/pnas.97.16.9026
  48. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Lead- and drug-like compounds: the rule-of-five revolution. Adv. Drug Delivery Rev. 2001;46:3-26. doi: 10.1016/S0169-409X(00)00129-0
Содержание
Оригинальная статья
Кашин И.А., Тузиков А.В., Андрианов А.М. Виртуальный скрининг новых ингибиторов проникновения ВИЧ-1, блокирующих CD4-связывающий участок белка gp120 оболочки вируса. Математическая биология и биоинформатика. 2014;9(2):359-372. doi: 10.17537/2014.9.359
(опубликована на рус. яз.)

Аннотация (рус.)
Аннотация (англ.)
Полный текст (рус., pdf)
Список литературы

 
  Copyright ИМПБ РАН © 2005-2025